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INTRODUCTION
Physical function can be assessed through physical examination with the use of performance-based measures and patient-
reported outcome measures (PROMs). Each form of assessment
provides a unique contribution to the understanding of the impact
of rheumatologic conditions on the patient. PROMs of physical
function (PF) are an important component of the assessment
of children with arthritis and have been included in the recommended core set of measures for childhood arthritis and musculoskeletal conditions. These measures provide the child’s or parent’s
perspective of function within the context of daily living. Measures
of PF include both generic measures, which are designed for use
across a spectrum of diseases and within healthy individuals, and
disease-specific measures, which are developed intentionally for
children with a rheumatologic or musculoskeletal condition. Most
PF PROMs include items that relate to daily functional activities,
but not all include aspects of daily living, play, and recreation,
which are activities essential to the physical, social, and emotional
development of children.
The use of PROMs for children with arthritis is influenced
by many factors. First, pediatric rheumatologic conditions are
heterogeneous. For example, juvenile idiopathic arthritis (JIA) has
seven established subtypes, including oligoarticular, systemic,
polyarticular rheumatoid factor (RF)–
positive, polyarticular RF-
negative, psoriatic, enthesitis-related, and undifferentiated arthritis
(1). Each subtype has distinct clinical features and differing ages
of onset. Other diseases, such as juvenile idiopathic inflammatory myositis (IIM) and systemic lupus erythematosus (SLE), also
vary in clinical presentation. In diseases with an early age of onset,
children’s cognitive abilities will limit the use of self-report, requiring
the use of proxy respondents (parent or guardian). Additionally,
the performance of PROMs within JIA subtypes is variable (2),
and measures are less available for the transition from childhood
to adulthood. Using the International Classification of Functioning,
Disability, and Health developed by the World Health Organization,
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the measures (3–12) described below include the following
domains: impairment (pain), activity limitations (activities of daily
living [ADLs]), participation restriction, and overall health status
(1,2) for use in children with JIA, juvenile IIM, and other musculoskeletal conditions. Some of these PROMs are generic measures
of PF (the Patient-Reported Outcomes Measurement Information
System–Physical Function Scale [PROMIS-
PF], Pediatric Outcomes Data Collection Instrument [PODCI], and Activity Scale
for Kids [ASK]), whereas others have been developed specifically
for children with juvenile arthritis (the Juvenile Arthritis Functional
Assessment Scale [JAFAS] and Child Health Assessment Questionnaire [C-
HAQ]) and for children with musculoskeletal conditions (the Knee Osteoarthritis Outcome Survey for Children
[KOOS-Child] and International Knee Documentation Committee
Subjective Knee Evaluation Form in Children [Pedi-IKDC]).

CHILDHOOD HEALTH ASSESSMENT
QUESTIONNAIRE
Description
Purpose. Singh et al (8) developed the C-HAQ to examine
functional health status in children (ages 1 to 18 years) with JIA.
The C-HAQ has since been evaluated in a variety of conditions,
including in children with chronic musculoskeletal pain, juvenile
dermatomyositis (DM), juvenile IIM, and SLE (13–17). The C-HAQ
is a core set measure recommended by the international research
networks in pediatric rheumatology (the Paediatric Rheumatology
International Trials Organization [PRINTO]) (18).
Content or domains. The C-HAQ includes a disability index,
which assesses the following eight domains of PF: dressing and
grooming, arising, eating, walking, hygiene, reach, grip, and activities. The disability index is supplemented with two visual analog
scales (VAS) as follows: one for pain (the discomfort index) and one
for global assessment of overall well-being (the health status index).
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Number of items. The disability index includes 30 items.
The discomfort index and health status index add one item each
to the tool.
Response options/scale. Each item within the C-HAQ disability index is scored on a four-point scale (0 = without any difficulty,
1 = with some difficulty, 2 = with much difficulty, and 3 = unable
to do). Respondents are prompted to indicate if assistance or aids
are needed to complete each talk. Reporting the use of assistance
or aids within a domain sets the score to a minimum of two for that
domain. Activities that the child is unable to do because he/she is
too young are marked as not applicable (N/A) for age.
Recall period. Respondents are asked to consider the
completion of tasks within the past week.
Cost to use. There is no cost when using the tool for
research purposes.
How to obtain. The C-HAQ can be obtained by contacting
Gurkirpal Singh (gsingh@leland.stanford.edu) or via websites such
as
http://www.niehs.nih.gov/research/resources/collab/imacs/
diseaseactivity.cfm.

Practical application
Method of administration. The C-
HAQ is typically
administered via paper and pencil using self-report for children
aged 8 years or older and proxy report (eg, parent or guardian)
for children less than 8 years of age. The C-HAQ is sometimes
administered via interview, particularly when it is being completed
for research purposes (19). Geerdink et al (20) developed a digital
version of the C-HAQ for the purpose of systematic monitoring in
clinical settings. The digital version was found to be both reliable
and user friendly (20).
Scoring. Within each of the eight domains, the item with the
highest disability score determines the score for that domain. The
global disability index is then obtained by calculating the mean of
the eight functional domains, with a range of 0 to 3. The two VAS
items (the discomfort index and the health status index) are measured on separate 15-cm scales. The distance from the left end of
the scale to the respondent’s mark is measured and multiplied by
0.2 to calculate the score, with a possible range of 0 to 3. Additional
information on scoring can be found at https://www.niehs.nih.gov/
research/resources/assets/docs/chaq_instructions_508.pdf.
Score interpretation. The disability index score ranges
from 0 (no disability) to 3 (disabled). A higher score indicates
a greater disability. This is a criterion-
referenced test; however, Dempster et al (21) found that the median C-HAQ scores
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 orresponding with mild, mild to moderate, and moderate disabilc
ity were 0.13, 0.63, and 1.75, respectively.
Respondent time to complete. The time to complete the
C-HAQ is 5 to 10 minutes.
Administrative burden. The administrative burden is low
because no special equipment or training is needed to administer
the C-HAQ. It takes approximately 2 minutes to score.
Translations/adaptations. Two alternate versions of the
C-HAQ exist (22). Groen et al (23) studied one of these alternative versions of the C-HAQ, the C-HAQ-38, to address limitations
related to ceiling effects when working with high-
functioning
patients with JIA. The C-HAQ-38 includes the addition of eight
items, which ask respondents to indicate the amount of difficulty
performing tasks more challenging than those included in the
original list of 30 tasks. The other alternate version of the C-HAQ,
the VASCHAQ, was modified from the C-HAQ-38 by removing
the consideration for aids and devices or help, using response
options in which questions are asked in relation to the child’s
peers, and using a 10-cm visual analog rating scale for each
question.
The C-
HAQ has been translated and culturally adapted
for use in more than 30 countries, including Argentina, Austria,
Belgium, Brazil, Bulgaria, Chile, Croatia, Czech Republic, Denmark, Finland, France, Georgia, Germany, Greece, Hungary,
Israel, Italy, Korea, Latvia, Mexico, Netherlands, Norway, Poland,
Portugal, Russia, Slovakia, Spain, Sweden, Switzerland, Turkey,
the United Kingdom, Yugoslavia (19), Saudi Arabia (24), and
Costa Rica (25) (Table 1).

Psychometric information
Floor and ceiling effects. The main limitation of the C-HAQ
is the potential for a ceiling effect, particularly when assessing functional improvements among higher-functioning children (ie, those
scoring closer to zero). Several authors have developed revised
versions of the C-HAQ to address the ceiling effect. Recommendations to avoid a ceiling effect and improve discriminant validity
include removing 12 redundant items (26), ignoring the domain
structure and the use of aids and assistance (13,26,27), and using
the C-HAQ-38, which includes eight additional items examining
respondent’s ability to complete more challenging tasks (23).
Reliability. Internal consistency has been demonstrated
among children with JIA with Cronbach’s α ranging from 0.88
to 0.96 (8,26,28–30). Takken et al (26) evaluated shorter versions of the C-HAQ disability index and found good internal consistency for both the 29-item and 18-item versions (Cronbach’s
α = 0.93 for both). Among children with juvenile IIM, there were
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significant item-total correlations ranging from 0.35 to 0.81, with
only four items with a correlation coefficient of less than 0.50.
Each C-HAQ domain also correlated well with the total C-HAQ
(r = 0.59-0.84) (14).
For the test-
retest reliability, which was studied at a
2-week interval, t-tests revealed virtually identical disability index
scores measured on the two occasions (0.96 versus 0.96; P > 0.9;
Spearman’s rank correlation coefficient = 0.8; P < 0.002) (8). Stephens et al (31) examined test-retest reliability at 2 to 6 weeks
among children with JIA and found very high reliability (intraclass
correlation coefficient [ICC] of 0.82). For patients with juvenile IIM
and less than a 10% change in VAS of overall illness severity, the
ICC was 0.96 (17).
Several studies have examined the correlation between
C-HAQ disability index scores from questionnaires administered
to parents and from questionnaires given to their children. All
correlations were moderate to strong (r = 0.54-0.84; P < 0.05),
demonstrating good interrater reliability (8,21,32,33).
Validity. The face validity of the instrument was first evaluated by a group of 20 health professionals and the parents of 22
healthy children (8).
To establish convergent validity, C-HAQ scores were compared with a variety of other PF measures. Van Mater et al (34)
conducted a systematic review of studies published between
1947 and 2010 that examined the validity of the C-HAQ and
found moderate correlations of the C-HAQ with the active joint
count (median correlation of 0.45 from seven studies) and limited
range of motion (ROM) (median correlation of 0.49 from nine studies). The C-HAQ was most strongly correlated with the parent/
patient assessment of global well-being (median correlation of
0.54 from six studies). Since this systematic review, Sontichai
and Vilaiyuk (35) identified a good correlation between the C-HAQ
disability index and the patient’s global assessment, physician’s
global assessment, and 27-joint Juvenile Arthritis Disease Activity
Score in all JIA subtypes during active disease (P < 0.05) but a
poor correlation between the C-HAQ disability index and disease
activity variables during inactive disease.
Regarding construct validity, Pouchot et al (36) examined
the validity of the C-HAQ in the following two age groups: children aged 10 years and younger and children older than 10 years
of age. They found that the difficulty of eight of 30 items of the
C-HAQ depends on the responder’s age. However, the impact
of this age-related variation on the C-HAQ disability index score
remained low (~0.25). As such, the authors concluded that the
C-HAQ design and scoring system remove most of the expected
bias related to physical development (36).
Responsiveness. C-HAQ responsiveness is variable in children with JIA, with effect sizes ranging from 0 to 0.5 (27,32,37–40),
and responsiveness is better among children with polyarticular JIA
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than those with oligoarticular JIA (34). In a study examining three
versions of the C-HAQ, the C-HAQ, VASCHAQ, and C-HAQ-38 all
demonstrated strong responsiveness when using self-report and
proxy report. The VASCHAQ, however, was found to be approximately 25% more responsive than both the original C-HAQ-30
and the C-
HAQ-
38 (41). In a study of children with juvenile
IIM enrolled at diagnosis, the responsiveness coefficient was
0.90 (17).
Minimally important differences. Among 92 families
with a child with JIA, the minimally clinical important difference
(MCID) for improvement of the C-HAQ was 0.188 at most; the
MCID for worsening was at most +0.125 (42). The authors concluded that the C-HAQ is relatively insensitive to important short-
term changes in children with JIA. In children with juvenile IIM
considered by their physician to have improved over 6 months,
the C-
HAQ showed a standardized response mean (SRM) of
1.3 (43).
Generalizability. The C-HAQ has been validated for use
with other disease conditions that impact PF among children,
including juvenile DM (17), active juvenile SLE (16), juvenile IIM
(17), and cerebral palsy (CP) (44), and with generalized musculoskeletal pain.
Use in clinical trials. The C-HAQ can be used to examine
the natural history of disease as well as improvements in PF in children with JIA and juvenile IIM after participation in exercise training
interventions (45) (Table 2).

Critical appraisal of overall value to the
rheumatology community
The C-HAQ’s major strength is its multidimensionality, including eight domains of PF. In addition, the C-HAQ is brief, simple,
and easy to administer and score. The C-HAQ is the most widely
used outcome measure by the rheumatology community and is
included as a pediatric rheumatology core set measure for JIA,
juvenile DM, and SLE. The C-HAQ has been culturally adapted for
use in more than 30 countries and is useful for both clinical and
research purposes. Bekkering et al (28) demonstrated no advantages of a performance test of PF as opposed to the C-HAQ
to measure functional disability in children with JIA.
The major limitation of the C-HAQ is the potential for a ceiling effect; the scale is less sensitive to milder levels of disability. Modified versions include eight high-level functional items to
address the ceiling effect and have removed the items referring
to the use of aids and devices for activities. The revised version allows for more normalized scores and demonstrated better
psychometric properties. Dempster et al (21) suggested that clinicians as well as researchers consider a minimum improvement
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of 0.13 in C-HAQ scores to indicate functional improvement in
children with arthritis.

Summary/recommendations
The C-HAQ is one of the most often used PROMs of PF
among children with JIA and other pediatric rheumatology conditions. The C-HAQ and its revised versions demonstrate good
reliability, validity, and responsiveness, suggesting its usefulness
in clinical decision-making and in research. They are simple, brief,
easy to use, and have been adapted for use in over 30 countries.
The original C-HAQ is limited by its ceiling effect. The revised versions demonstrate better psychometric properties and, thus, are
preferred to the original C-HAQ (13,23,26,27).

JUVENILE ARTHRITIS FUNCTIONAL
ASSESSMENT SCALE
Description
Purpose. The JAFAS was developed by Lovell et al (5) as
the first normalized measure to assess disability in children with
JIA ages seven years and older in clinical settings. The JAFAS
was developed for use in the US Bureau of Maternal and Children
Health and Resources Development Project.
Content or domains. The JAFAS requires the assessor to
observe the child performing 10 ADLs deemed difficult for children
with arthritis to perform (eg, getting out of bed, dressing, picking
an object up off the floor).
Number of items. The JAFAS includes 10 items.
Response options/scale. The therapist observes the child
performing activities and records the time it takes for the child to
complete each task.
Recall period. Not applicable.
Cost to use. There is no cost to use the JAFAS for research
purposes.
How to obtain. The JAFAS and its scoring manual can be
obtained in the article by Lovell et al (5).

Practical application
Method of administration. The JAFAS is an observation measure that is to be administered by a physical or occupational therapist in a clinical or office setting. Activities are timed and
compared with a criterion value noted on the form.
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Scoring. The JAFAS is scored by hand. If a task is completed in less than or equal to the criterion time, then the task is
scored as 0; if it is completed but requires longer than the criterion
time, the task is scored as 1; if the patient is unable to perform the
task, the task is scored as 2. The scores for each task are then
summed for a total JAFAS score. The possible range of scores is
0 to 20.
Score interpretation. A higher score indicates a greater
level of disability. When the JAFAS was initially tested, control-
group patients scored a mean of 0.43 (SD 0.86) and patients with
JIA scored a mean of 3.39 (SD 3.42).
Respondent time to complete. It usually takes a child
approximately 10 to 15 minutes to complete the activities.
Administrative burden. The JAFAS is relatively easy
to administer and only takes 10 to 15 minutes. It does require
a trained professional (training time is minimal) and standardized
equipment, making the administrative burden higher than that of a
paper-and-pencil questionnaire.
Translations/adaptations. The JAFAS has been culturally adapted for use among Indian children (46). The Indian
version has internal consistency reliability similar to that of the
C-HAQ (Table 1).

Psychometric information
Floor and ceiling effects. To date, no floor or ceiling
effects have been reported for the JAFAS.
Reliability. Lovell et al (5) found that the mean interitem correlation of the JAFAS in the population with JIA was
0.36, indicating that the items capture different aspects of
function. Internal consistency for the JAFAS varies from moderate to good, with a Cronbach’s α ranging from 0.81 to 0.92
(5,28,30).
Validity. Regarding content validity, the JAFAS was
developed from a range of tasks derived from the McMaster Health Index Questionnaire, the Arthritis Impact Measurement Scale, and the Health Assessment Questionnaire. An
expert panel of pediatric physical and occupational therapists experienced in working with children with JIA reviewed
items to ensure that the activities involved all aspects of
the body during daily activities and were easy to measure
objectively.
Lovell et al (5) established convergent validity among a group
of patients with JIA; they found that the JAFAS was significantly
correlated with the number of involved joints (r = 0.40; P = 0.003),
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Steinbrocker functional class (r = 0.59; P = 0.0001), and disease
activity (r = −0.32; P = 0.01).
Bekkering et al (28) examined disability in 28 children with
JIA and found that JAFAS and C-HAQ scores were positively
correlated (r = 0.55; P < 0.01). The JAFAS was also correlated
with measures of disease activity and joint counts, including
swollen joints (r = 0.47; P < 0.05), physician’s evaluation of
disease activity (r = 0.41; P < 0.05), joint count on motion-
restricted joints (r = 0.44; P < 0.05), and the pediatric Escola
de Paulista de Medicina ROM scale (47) (r = 0.50; P < 0.01),
demonstrating convergent validity. There was no significant
association between JAFAS scores and erythrocyte sedimentation rate and joint count on tender joints. There does appear
to be a floor effect when using the JAFAS in relatively high-
functioning children.
Responsiveness. The ability of the JAFAS to capture
change in children’s PF was assessed in a study examining the
impact of intra-articular injections in 92 children with JIA and was
found to be moderate at the 6-week evaluation (SRM 0.41; 95%
confidence interval [CI] 0.18-0.64) (48).
Minimally important differences. Minimally important
differences have not been reported for the JAFAS.
Generalizability. Although the JAFAS was developed for
children with JIA, it can be used to assess function and musculoskeletal involvement in children with SLE who have compromised PF.
Use in clinical trials. The JAFAS has been used in studies
of exercise in children with JIA (49) (Table 2).

Critical appraisal of overall value to the
rheumatology community
The JAFAS provides reference values for the 10 ADLs performed by the child and scores the child based on the time it
takes to complete the activity. The JAFAS has clear, concise,
and understandable directions for use and has been shown to
correlate well with other measures of disease activity and movement. The biggest limitation is the need for a trained observer
and standardized equipment in the clinical setting. The JAFAS
also does not include play and recreation items and is limited to
10 activities. There is no information on how to handle missing
items. The JAFAS has been used in clinical trials of intra-articular
joint injections in children with JIA. Bekkering et al (28) indicated
the Juvenile Arthritis Functional Assessment Report (JAFAR)
could be as useful as the JAFAS and has less administrative
burden.
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Summary/recommendations
Although the JAFAS has been shown to be reliable and
valid, there are limited data on its ability to assess change
following an intervention, and it requires the use of a trained
observer. The JAFAS measures function as it relates to 10
ADLs and may be best suited for children with limited ROM
and strength deficits. The JAFAS does not provide an assessment of the child’s ability to engage in play and recreation.
Other existing measured such as the C-HAQ and JAFAR may
be more efficient for use in clinical practice and research
because the C-HAQ has the added benefit of having responsiveness data.

JUVENILE ARTHRITIS FUNCTIONAL STATUS
INDEX (JASI)
Description
Purpose. The JASI assesses PF status and ADLs in children with JIA, ages 8 to 18 years (50). Items for the JASI were
developed based on interviews of children, parents, teachers,
and clinicians.
Content or domains. The JASI Part I includes 100 items
divided into five activity categories (self-care, domestic, mobility,
school, and extracurricular). The JASI Part II is a priority function
section in which children are asked to identify and score activities
for which they want to see improvement (51).
Number of items. Part I includes 100 items, and Part II
includes five items.
Response options/scale. A seven-
point degree of
difficulty rating scale is used for responses (6 = as well as
friends/family without arthritis; 5 = it is a little difficult; 4 = it
is very difficult; 3 = using special equipment; 2 = with a little help from someone; 1 = with a lot of help from someone;
0 = someone has to do it for me or I cannot do it because of my
arthritis).
Recall period. The recall period of time is the current
status.
Cost to use. There is a fee for the training manual and software, which can be obtained from the developer.
How to obtain. The JASI can be obtained from Dr. Wright
at Bloorview Research Institute, Holland Bloorview Kids Rehabilitation Hospital, 150 Kilgour Road, Toronto, Ontario M4G 1R8,
Canada (vwright@hollandbloorview.ca).
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Practical application
Method of administration. The child completes Part I
on a computer; Part I takes approximately 20 to 45 minutes to
complete. For Part II, the child is interviewed; the interview takes
approximately 20 minutes to complete.
Scoring. Part I is automatically scored using computer software. Part II is scored by hand according to the test manual. The
Part I range of scores is 0 to 600. The Part II range of scores is 0
to 30.
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Minimally important differences. Minimally important
differences have not been established in the literature.
Generalizability. The JASI is not appropriate for use in children aged 7 years or younger.
Use in clinical trials. Because of the time to administer, the need for training and special equipment, and its weak
to moderate responsiveness, its use in clinical trials has been
limited (Table 2).

Score interpretation. Lower scores reflect greater disability. This is a criterion-referenced test.

Critical appraisal of overall value to the
rheumatology community

Respondent time to complete. Time to complete is not
reported in the literature.

The major strength of the JASI is that it examines function
across a range of environments (eg, home, school, and play). The
JASI was developed using rigorous methodology and involved
patients, parents, clinicians, and teachers in the item generation. Limitations of the JASI include the length of time it takes for
children to complete both portions of the JASI, the reliance on
computer software for Part I, and although minimal, the cost for
the software, which might deter some from using the JASI versus
other valid and reliable assessments of functional status available
for free. The JASI is also not appropriate for use in children aged
7 years or younger.

Administrative burden. The test is relatively time-
consuming, taking approximately 40 minutes to administer, and
requires computer software and a test manual, which can be
obtained from the authors who developed the tool.
Translations/adaptations. The JASI has not been translated or culturally adapted (Table 1).

Psychometric information
Floor and ceiling effects. The JASI has no reported floor
or ceiling effects.
Reliability. To determine test-
retest reliability, Wright
et al (51) administered the JASI to 30 children with JIA between
8 and 19 years of age at baseline, 3 weeks, and 3 months
(51). Reliability of the JASI Part I was excellent at 3 weeks
(ICC = 0.98) and 3 months (ICC = 0.99). Reliability was lower
for respondents with mild disease than those with polyarticular
JIA. Test-retest reliability for the JASI Part II was fair (κ = 0.57).
Validity. Seventeen clinicians reviewed the questionnaire
and rated the index as a credible functional measure of JIA, establishing content validity (50). When tested for construct validity,
JASI Part I scores correlated strongly with joint count (r = 0.51),
grip strength (r = 0.64), hip synovitis (r = 0.64), timed walk and run
(r = 0.83), and American College of Rheumatology functional class
(r = 0.80) (51).
Responsiveness. Brown et al (32) examined the responsiveness of the JASI during a 4-year prospective study in which
children with JIA were receiving intra-articular steroid injections
and methotrexate treatment. The JASI demonstrated weak
to moderate responsiveness to change, with an SRM of 0.36.

Summary/recommendations
JASI is a well-
developed PF measure for children with
arthritis. It provides a comprehensive picture of function across
a spectrum of activities and allows the child to rank what the
child perceives are the most important issues to change. Given
its length and equipment/training needs, its use in daily clinical
practice is limited.

PEDIATRIC ORTHOPEDIC SURGEONS OF
NORTH AMERICA (POSNA) PODCI, FORMERLY
THE PEDIATRIC MUSCULOSKELETAL
FUNCTIONAL HEALTH QUESTIONNAIRE
Description
Purpose. The POSNA PODCI, formerly known as the
POSNA Pediatric Musculoskeletal Functional Health Questionnaire, assesses functional health outcomes, specifically musculoskeletal health (pain, participation in daily activities as well
as vigorous activities) for both healthy children and adolescents
and those with musculoskeletal conditions (52). The PODCI
was developed as a patient-centered measure that could be
used across a wide range of ages and musculoskeletal disorders for the clinical assessment of treatment effectiveness
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and musculoskeletal research. The PODCI has a child version
to be completed by a parent/physician proxy and two surveys
for adolescents (one that can be completed by a proxy and
one that can be completed by self-report). For the purpose of
this measure, a child is defined as being 2 to 10 years old, and
an adolescent is between 11 and 18 years old.
Content or domains. The PODCI includes the following
subscales that examine upper extremity (UE) and PF, transfers
and basic mobility (TBM), sports and PF (SPF), pain/comfort (PC),
happiness (HAP), and a global function score (GFS). The original
questionnaire included a treatment expectations scale (52), but
this was excluded in later versions (53).
Number of items. The original questionnaire had a total of
114 items, and the average time to complete was approximately
15 minutes for the adolescent version and 10 to 12 minutes for
parent versions. The newer version (PODCI) has 83 items and five
subscales for the adolescent version and 86 for the parent versions. Within the five scales, the TBM has 11 items, the SPF has
21 items, the PC has three items, the UE has eight items, and the
HAP subscale has five items.
Response options/scale. The response options vary,
with some nominal items (yes/no) and some ordinal scales. The
range for the ordinal scales is either a four-point or five-point scale,
depending on the question. For the additional comorbidity scale,
there is a list of diseases, and the proxy or adolescent responds
to whether the child/adolescent has the condition, is receiving
treatment for the condition, and whether it limits activity. For a
few items, there is the option to select that the child is too young
to do the activity. If this is selected for an item, the item is treated
as missing and omitted from the score.
Recall period. The reference period is 1 week for all items
except for one item that asks for recall over 1 year.
Cost to use. There is no cost to use this questionnaire.
How to obtain. The PODCI can be obtained from the
American Academy of Orthopedic Surgeons (AAOS) website
(http://www.aaos.org/research/outcomes/outcomes_peds.asp).

Practical application
Method of administration. The PODCI is a pen-and-paper
survey. The survey provides clear instructions regarding the reference time period and response categories. A proxy (parent or guardian) completes the parent/child questionnaire for children aged 2 to
10 years. The parent/adolescent questionnaire can be completed
either by the parent as a proxy or by the adolescent as self-report.
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Scoring. A formula is provided and is used to compute a
standardized score for each subscale using the raw score. In brief,
all items in the subscales are converted so that the vales range from
0 to 5. Then, the scores for all items in a subscale are averaged
for those items that are not missing. The mean of the subscales
is multiplied by a constant value to generate a score range of 0 to
100 (52). A minimum of 50% of the items in a scale must have a
response for the scale score to be computed. When assessing a
young child using the parent proxy, roughly 0% to 25% of items are
often missing because of the inability to score the child in specific
domains, including HAP and satisfaction. The GFS is calculated by
taking the mean of the “mean of items” in the first four subscales.
Comorbidity subscales and a comorbidity index, which computes
an average of the responses, are calculated. The AAOS provides
an Excel file on its website to score the raw data. Each worksheet
has the formula embedded for the specific subscale.
Score interpretation. Higher scores indicate more of the
specific trait measured by the subscale. Haynes and Sullivan (53)
used the questionnaire with 57 healthy children and 27 healthy
adolescents and determined that a child scoring in the low 80s
or lower is functioning at a different level than a healthy child. The
AAOS has a large national database that uses the PODCI and
provides access to normative data and enables analysis by age,
sex, and comorbidity (54). Normative values exist for the PODCI
(53,55). To calculate a normative value for a patient, subtract the
population standardized mean from the patient’s score and then
divide this value by the population SD and multiply the new value
by 10 and add 50 to the final value.
Respondent time to complete. It takes approximately
15 minutes to complete (56).
Administrative burden. The administrative burden is low
because no special equipment or training is needed. The scoring
is calculated using the Excel file available from AAOS.
Translations/adaptations. The PODCI has been translated and culturally validated in Korean (57), Spanish (58), Dutch
(59), Polish (60), Turkish (61), and Brazilian Portuguese (62) (Table 1).

Psychometric information
Floor and ceiling effects. Floor and/or ceiling effects have
not been identified for this outcome measure.
Reliability. Daltroy et al (52) examined test-retest reliability
over 1 to 2 days using Pearson’s correlation coefficients. Test-
retest reliability was good to excellent among both parents and
adolescents for the following subscales: GFS (parents = 0.97;
child = 0.95), UE (parents = 0.94; child = 0.96), SPF (parents = 0.93;
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child = 0.87), TBM (parents = 0.96; child = 0.97), PC (parents = 0.83;
child = 0.89), HAP (parents = 0.71; child = 0.87), and expectations
(parents = 0.83; child = 0.76).
Based on parent report, Cronbach’s α ranged from 0.82
to 0.95 across subscales. Based on child report, Cronbach’s α
ranged from 0.76 to 0.92 across subscales. Overall, internal consistency was stronger when parents reported on outcomes than
when children did. Parent-child agreement was good for the GFS
and PC (r = 0.84), UE (r = 0.83), SPF (r = 0.87), TBM (r = 0.86),
and PC (r = 0.76) but was weak for HAP (r = 0.50) and the expectations scale (r = 0.45). The Dutch PODCI UE and SPF subscales
and total GFS showed good internal consistency (Cronbach’s α
0.695-0.781) and reliability (ICC = 0.97-0.80) and were significantly
associated with active ROM and the Mallet score in neonates with
brachial plexus palsy. After surgery, a significant change of the
total score (effect size 0.57; SRM 1.23; change of 4.22 points,
95% CI 1.04-7.4) was seen (59).
Validity. Convergent validity was established by Daltroy
et al (52), who found that the physician’s pain score was correlated with the parent’s pain score and that the physician’s score
of global function and diagnosis severity were correlated with
parent’s and adolescent’s function scores. Boyer et al (63) also
demonstrated convergent validity because post-traumatic stress
severity correlated with all subscales and global function and post-
traumatic stress disorder diagnosis was significantly related to two
subscales, as well as global function, among individuals with pediatric spinal cord injury. Daltroy et al (52) established discriminant
validity because the physician’s pain measure was not correlated
with function, HAP, or expectations scores, and the physician’s
assessments of function were not correlated with the parent’s or
adolescent’s HAP, PCF, or expectations scores.
Responsiveness. Daltroy et al (52) assessed responsiveness by examining changes in musculoskeletal function over
9 months, using the Child Health Questionnaire as a comparison
and found it was sensitive to change among patients with moderate to severe musculoskeletal issues at baseline.
Minimally important differences. An MCID was calculated for 381 ambulatory children with CP with gross motor function classifications of I to III and a mean age of 11 years (64).
Generalizability. The PODCI can be used for children
with a variety of musculoskeletal and neuromuscular conditions
(eg, idiopathic scoliosis, osteogenesis imperfecta, UE amputation, congenital UE differences, CP, and sports injuries) and with
healthy children.
The PODCI subscales differentiated between the various topographical types of vertebral palsy among children (65), indicating
the measure is a valid and useful for assessing function among
children with CP.

GREER AND IVERSEN

Use in clinical trials. The PODCI has been used in clinical trials and research and to establish normative data in healthy
children (Table 2).

Critical appraisal of overall value to the
rheumatology community
The PODCI was developed using rigorous methodology;
items were created that included domains important to children
and their parents and with consensus of experts. The questionnaire was pilot tested with 112 parents and 64 adolescents,
and following completion of the survey, each participant was
debriefed to gather feedback on the structure and content.
Strengths of the PODCI are as follows: no cost nor equipment
is needed, it is clear and easy to read, it includes a wide breath
of domains, it uses higher-level PF activities, it has response
sets which can be used by various age groups, it can be used
in various musculoskeletal conditions, it has the ability to compare parent and adolescent scores, and normative data exist
to assist in interpretation of scores. One study has reported
the MCID for the PODCI in ambulatory children with CP. The
scoring is complex, but the AAOS provides clear directions for
scoring and an Excel file with the formulas embedded. The proportion of children with arthritis in the sample used to examine
the initial testing of psychometric properties of the PODCI was
limited (~5%). When using the PODCI, results should be considered in the context of age, sex, and comorbidity impacts (52)
on scores.

Summary/recommendations
The PODCI subscales demonstrate good reliability, construct validity, and sensitivity to change over 9 months, making it
well suited for clinical research. The PODCI is relatively brief and
came be completed in approximately 15 minutes. The PODCI
can be used for children of various ages and musculoskeletal
conditions. The PODCI appears to be useful to assess function
and intervention efficacy following surgical orthopedic interventions as well as medical and rehabilitation interventions. Given its
strong psychometric properties, the PODCI can be used in clinical practice, with scoring completed using the published Excel
scoring format.

JUVENILE ARTHRITIS MULTIDIMENSIONAL
ASSESSMENT REPORT (JAMAR)
Description
Purpose. The JAMAR is used to examine disease activity
and disability among children with JIA (66), and it contains items
deemed relevant by parents and children. The JAMAR is recommended by the PRINTO.
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Content or domains. The JAMAR includes items addressing well-being, pain, function, health-related quality of life, morning
stiffness, disease activity, disease status, joint and extraarticular
disease, compliance, side effects, and overall satisfaction with
illness outcome.
Number of items. The JAMAR includes 15 components.
Some of the components are single-item measures; the longest
component within the JAMAR is 15 items.
Response options/scale. The response options/scale for
each of the 15 components within the JAMAR are listed by subscale. The PF subscale has 15 items that score the child’s ability
to complete each task as follows: 0 = without difficulty, 1 = with
some difficulty, 2 = with much difficulty, 3 = unable to do, and N/A
if it was not possible to answer the question or the patient was
unable to perform the task because of their young age or for reasons other than JIA. The total PF score has three components:
PF lower limbs (PF-LL); PF hand and wrist (PF-HW), and PF upper
segment (PF-
US), each scoring from 0-
15 (37). Pain intensity
is rated on a 21-numbered circle VAS (0 = no pain; 10 = very
severe pain) (67). The Pediatric Rheumatology Quality of Life Scale
(HRQoL) (68) includes two subdimensions, physical health (PhH)
and psychosocial health (PsH). Each component has five items.
The responses are never (score = 0), sometimes (score = 1), most
of the time (score = 2), and all the time (score = 3). Overall well-
being is measured using a 21-numbered circle VAS (0 = very
well; 10 = very poorly), and disease activity is measured on a
21-numbered VAS (0 = no activity; 10 = maximum activity) (67).
Joint pain and swelling are indicated by their presence or
absence for the following joints: cervical spine, lumbosacral
spine, shoulders, elbows, wrists, small hand joints, hips, knees,
ankles, and small foot joints. Morning stiffness and extraarticular
symptoms (eg, fever or rash) are also recorded as present or
absent. Disease status at the clinical visit is noted as remission,
continued activity, or relapse. The patient’s disease course is
compared with the prior visit and recorded as much improved,
slightly improved, stable, slightly worsened, or much worsened.
The JAMAR includes a list of medications the child may be taking along with a list of side effects of medications and difficulties
with taking medications. A list of items related to problems with
school due to the child’s JIA is provided, and the final component is an item regarding satisfaction with the outcome of the
illness (yes/no).
Recall period. The recall period within JAMAR differs
according to the specific measure. The measures within the
JAMAR ask respondents to consider their symptoms and experiences in the moment, today, in the past week, in the past 4
weeks, and since their last doctor visit.
Cost to use. The JAMAR is free to use.
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How to obtain. The JAMAR can be obtained from the
original article (66), available at http://www.jrheum.org/content/
38/5/938.long#app-1.

Practical application
Method of administration. The JAMAR can be used as
both a proxy report and a patient self-report, with the suggested
age range of 7 to 18 years for use as a self-report. The JAMAR
is simple and language-level appropriate (ie, 80% of the children
could read the survey without difficulty).
Scoring. Responses to the scales and subscales (PF-
LL, PF-HW, PF-US, HRQoL, HRQoL-PH and HRQoL-PsH) are
summed. The total PF score ranges from 0 to 45. The HRQoL
total score ranges from 0 to 30. A separate score for the PhH and
PsH subscales (range: 0-15) can be calculated.
Score interpretation. Higher scores on any scale indicate
greater disability.
Administrative burden. Both parents and children have
reported that the questionnaire was simple and easy to understand
(66). It takes under 15 minutes to complete the questionnaire and
5 minutes to score the questionnaire. No special equipment or
training is needed. Because of this, administrative burden is low.
Translations/adaptations. The original measure was
developed in Italian and then translated into English (66). Bovis
et al (69) culturally adapted and translated the JAMAR into 54
languages for use in 52 difference countries that are members
of the PRINTO. The countries included in the validation study
were Algeria, Argentina, Belgium, Brazil, Bulgaria, Canada, Chile,
Colombia, Croatia, Czech Republic, Denmark, Ecuador, Egypt,
Estonia, Finland, France, Georgia, Germany, Greece, Hungary,
India, the Islamic Republic of Iran, Israel, Italy, Latvia, Libya, Lithuania, Mexico, Netherlands, Norway, Oman, Paraguay, Poland,
Portugal, Romania, the Russian Federation, Saudi Arabia, Serbia,
Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland,
Thailand, Turkey, Ukraine, the United Kingdom, and the United
States. The JAMAR demonstrated good psychometric properties
across adaptations (Table 1).

Psychometric information
Floor and ceiling effects. No floor or ceiling effects have
been reported.
Reliability. With regard to agreement between parent
proxy and child self-reported data in paired questionnaires,
findings are mixed (66,70). Filocamo et al (66) found that
responses for parent-child pairs were similar for most items
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other than one question about medication side effects, in which
parents more often reported hypertrichosis as a side effect.
Vanoni et al (70) found an increased number of items with disagreement between parents and children when the disease
was more active.
Filocamo et al (66) examined whether the child’s age affected
the reliability of completion of the questionnaire. Results across
the three age groups (less than 10, 10-15, and more than 15
years) were comparable, with the exceptions of a lower correlation
of functional ability assessment in the younger age group and of
psychosocial HRQoL assessment in the older age group. Internal
consistency for the US English version of JAMAR was adequate.
Specifically, Cronbach’s α was 0.88 for PF-LL, 0.87 for PF-HW,
and 0.72 for PF-US. Cronbach’s α was 0.86 for HRQoL-PH and
0.77 for HRQoL-PsH. In the English version, test-retest reliability
assessed a median of 3 days after initial measure was excellent
(ICC = 0.92). Additionally, the ICC for the HRQoL-PhH and for
the HRQoL-PsH was almost perfect (ICC = 0.92 and ICC = 0.83,
respectively) (71).
Validity. Face validity was established first by content
review of medical personnel, including 12 physicians (eight
pediatric rheumatologists and four pediatric residents), four
physical therapists, three specialist nurses, and one clinical
psychologist. Additionally, a sample of 49 children with JIA and
their parents completed the draft questionnaire and provided
comments about the design, content, structure, and response
scale (66).
JAMAR scores were compared with clinical measures of
disease activity and severity to determine discriminant validity. Specifically, the functional ability and HRQoL scores and
VAS worsened as the number of affected joints increased. In
addition, in patients with more affected joints, the frequency of
remission was lower, and the frequency of continued activity
and disease flare was higher (66). With regard to the US English
version of the JAMAR, the JAMAR components discriminated
well between healthy subjects and patients with JIA. Patients
with JIA had a greater level of disability and pain as well as
a lower HRQoL than their healthy peers (71). With regard to
external validity, Spearman’s correlations of the PF and HRQoL
scales with measures in the JIA core set were weak to moderate (71).
Responsiveness. Hussein et al (72) used the JAMAR to
examine the experiences of 44 children with JIA who attended
the pediatric rheumatology clinic in Alexandria University Children’s Hospital in Egypt from baseline to 6 months. They found
the JAMAR to be sensitive to changes in disease activity from
baseline to 6 months.
Minimally important differences. Minimally important
differences have not been established for the JAMAR.
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Generalizability. The JAMAR has been used to examine
disease activity among patients with JIA in 52 countries around
the world (72).
Use in clinical trials. To date, the JAMAR has not been
used in clinical trials (Table 2).

Critical appraisal of overall value to the
rheumatology community
The JAMAR is a valid tool for the assessment of children with
JIA and has been translated in numerous languages and culturally
validated. The JAMAR provides a systematic review of the child’s
status, enabling a more efficient clinical visit and assessment of
JIA and its management. The JAMAR demonstrates strong psychometric properties and is suitable for use in both clinical practice and clinical research. However, the JAMAR might not obtain
sufficient detail regarding patient outcomes related to sleep disturbances, fatigue, coping, and family life (37).

Summary/recommendations
The JAMAR is a comprehensive tool used to assess the
impact of JIA and its treatment on functional performance in children with JIA. It is easy to read, with understandable response sets.
The psychometric properties are good, although responsiveness
needs further evaluation. This PROM is one of the most translated
and culturally adapted measures designed for children with arthritis.

KNEE OSTEOARTHRITIS OUTCOME SCORE
FOR CHILDREN
Description
Purpose. The KOOS-Child was designed to assess perception of knee and associated knee problems among children ages
10 to 16 years old. The original KOOS-Child LK was replaced with
an updated version, LK 2.0, to account for a flip of response scales.
Content or domains. There are five subscales of the
KOOS-Child: knee pain, knee symptoms, ADLs, sports and play,
and quality of life. No composite score is reported.
Number of items. The KOOS-Child includes 39 items,
including seven items regarding symptoms, eight items regarding
pain, 11 items regarding ADLs, seven items regarding sports and
play, and six items regarding quality of life.
Response options/scale. Each item uses a five-
point
Likert scale. The average scores for each subscale are normalized and range from least severe to most severe (0-4) or never to
always (0-4), depending on the item.
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Recall period. Respondents are asked to recall symptoms
over the past 7 days.
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Translations/adaptations. The KOOS-Child is available
in Danish, Dutch, English, Finnish, Greek, Norwegian, Persian,
and Swedish (Table 1).

Cost to use. The KOOS-Child is free to use.
How to obtain. The KOOS-Child can be obtained online for
free at http://www.koos.nu/.

Practical application
Method of administration. The KOOS-
Child is completed using paper and pen and can be administered in person
or via postal mail.
Scoring. Each subscale within the KOOS-Child is scored
separately and normalized to create a score ranging from 0 to
100 for each subscale. This enables the clinician or researcher
to create a profile for each patient or report in the aggregate.
To calculate a subscale score, sum the scores of the specific subscale items (eg, seven symptom items) and calculate
the mean of subscale. Next, multiply the mean of the subscale
by 100, divide by 4, and subtract this value from 100 (73). Note
that there was an edit to the primary scale, so check scoring
depending on the version used. Questions regarding scoring of
the KOOS-Child can be directed to the web manager at webmanager@koos.nu.
Score interpretation. A score of 100 indicates no symptoms, and a score of 0 indicates extreme symptoms. In a study of
1000 healthy individuals (adults and children) ages 8 to 101 years,
normative data are reported for children 8 to 17 years, stratified
by sex for each of the subscales (74). Scores for the male children’s pain, symptoms, ADL, sport/recreation, and quality of life
subscales and KOOS total scale were as follows: mean 95.7 (SD
10.7), mean 95.8 (SD 8.3), mean 99.1 (SD 3.4), mean 97.8 (SD
5.8), mean 97.3 (SD 7.2), and mean 97.1 (SD 6.1), respectively.
Scores for the female children’s pain, symptoms, ADL, sport/recreation, and quality of life subscales and KOOS total scale were as
follows: mean 92.2 (SD 14.0), mean 93.1 (SD 11.4), mean 96.4
(SD 7.6), mean 93.2 (SD 13.7), mean 94.4 (SD 13.7), and mean
93.8 (SD 11.0), respectively.
Respondent time to complete. The KOOS-
Child is
simple to complete and takes roughly 10 to 20 minutes, with
younger children taking closer to the longest window of completion time (75). Younger children may also need some help with
reading the items.
Administrative burden. The KOOS-Child takes about 10
to 20 minutes for a child to complete. The scores can be calculated by hand. No special software is needed to calculate the
KOSS-Child subscales.

Psychometric information
Floor and ceiling effects. No floor to ceiling effects were
found using a threshold of 15% or less (73). In the Dutch version,
low floor and ceiling effects (scores between 5 and 95, except for the
KOOS-Child subscales for ADLs and sport/play) were identified (76).
Reliability. Internal consistency was good to excellent
across all subscales (Cronbach’s α = 0.80-0.90) except for the
symptoms subscale (Cronbach’s α = 0.59). Test-retest reliability
was assessed among 72 children with an average of 11 days from
the first to the second administration. The ICC for the symptoms
subscale was 0.78; for all other subscales, the ICC ranged from
0.85 to 0.91 (73). In the Dutch version, the KOOS-Child showed
an adequate test-retest reliability (ICC = 0.8-0.9; SEM = 8.9-16.9;
smallest detectable change [SDC] = 24.7-46.9), depending on the
subscale (76).
Validity. Comprehensibility and content validity of the
KOOS-Child were assessed in 34 Swedish children aged 10 to
16 years who had symptomatic knee injuries (74). The original
KOOS was not well understood by children. As such, modifications related to comprehension, mapping of responses, and jargon were made based on qualitative feedback from the children
in order to develop the KOOS-Child. Content validity was later
established in the Dutch version (75) of the KOOS-Child (more
than 75% relevant, except for the KOOS-Child ADLs subscale).
In original psychometric testing (73), construct validity was
confirmed by convergence with similar items from the C-HAQ, the
EuroQol for youth, and five purpose-specific VAS items. All a priori
hypotheses were confirmed during psychometric testing, indicating that there was excellent construct validity. Greater effect sizes
were seen in those reporting improved clinical status. In the Dutch
version, there was adequate construct validity (75% confirmed
hypotheses) (76).
Responsiveness. To assess responsiveness, a KOOS-Child
questionnaire was mailed with a global perceived-effect (GPE) scale
3 months after the initial assessment (73). This time frame was
selected because it is often when a clinical improvement in the study
sample can be expected. Changes in the final KOOS-Child subscale scores between baseline and 3 months administration were
assumed to correlate 0.3 or more with the subscale-specific GPE
scores. All subscales demonstrated responsiveness to change,
with a moderate effect size (0.42-0.78) in patients who reported an
improvement in their symptoms and a small effect size (0.12-0.21) in
patients who reported stable symptoms. In the Dutch version, moderate responsiveness was found (40% confirmed hypotheses) (76).
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Minimally important differences. The SDC of the
KOOS-Child subscales ranged from 24.7 to 46.9 (76).

not been modified since its initial publication. The Pedi-IKDC is
written at the fifth-to sixth-grade reading level.

Generalizability. The KOOS-Child can be used to assess
children with a variety of knee injuries, including but not limited
to anterior cruciate ligament injuries, patella dislocations, meniscal tears, and chondral injuries. The KOOS-Child is designed to
assess both individual change and group change and to assess
short-term and long-term changes in knee function, symptoms,
and quality of life. The KOOS-Child can be used for children with
a variety of symptomatic knee conditions.

Content or domains. The Pedi-
IKDC was developed
using qualitative interviews among children to critically evaluate
the comprehension and relevance of the International Knee Documentation Classification (IKDC) for use in children and then modified accordingly (78). The Pedi-IKDC examines PF, participation in
sports/recreation, and ADLs. The form also includes some demographic and medical history items.
Number of items. The Pedi-IKDC includes 13 items.

Use in clinical trials. The KOOS-Child has been used
in both surgical and nonsurgical intervention trials (77) and has
shown strong psychometric properties (Table 2).

Critical appraisal of overall value to the
rheumatology community
The KOOS-Child is recommended for use in clinical practice
and research to evaluate knee function, symptoms, and knee-
related quality of life in children with knee disorders. A change of 2
to 3 and 15 to 23 KOOS-Child points is needed at group and individual levels, respectively, to detect a true change over time. A major
strength of the KOOS-Child is that it can be used to create a profile
for an individual using each subscale. Additionally, the inclusion of
the sports and recreation scale provides needed data not obtained
with standard measures of PF in children. However, the KOOS-
Child should not be used in children younger than 7 years. The
KOOS-Child is not intended for use as a parent proxy measure.

Response options/scale. The Pedi-IKDC uses a mix of
response sets. Some items use a Likert scale ranging from 1 to 5;
whereas others use a 10-point VAS with verbal anchors at each
end to indicate level of difficulty performing an activity (not able to
able to perform or extreme symptoms to no symptoms). There are
two dichotomous items in the symptom scale.
Recall period. Most items ask children to recall symptoms
and function over the past 4 weeks. Some items ask children to
estimate symptoms/function based on whether they believe they
could do the activity today.
Cost to use. There is no cost to use the Pedi-IKDC.
How to obtain. The Pedi-IKDC form can be obtained at
https://www.sportsmed.org/aossmimis/Staging/Research/IKDC_
Forms.aspx.

Summary/recommendations

Practical application

The KOOS-Child has strong psychometric properties and
provides the clinician and researcher with the ability to create a
physical activity profile. The comprehensibility of the KOOS-Child
was assessed and ensures children ages 7 to 16 years can clearly
understand the items and select an appropriate response. The
inclusion of sports and play in the measure provides important
information not typically found in PF PROMs. The KOOS-Child
is well suited for assessment of intervention, clinical decision-
making, and clinical research.

Method of administration. The Pedi-IKDC is administered via paper and pencil.

PEDIATRIC INTERNATIONAL KNEE
DOCUMENTATION CLASSIFICATION
Description
Purpose. The Pedi-IKDC was the first knee-specific PROM
to be rigorously validated in a pediatric population. It was designed
to assess knee pathology in children ages 10 to 18 years. It has

Scoring. Persons scoring the Pedi-IKDC should assign the
appropriate numerical scores to the individual’s response for each
item such that lowest score of 0 represents the lowest level of
function or the highest level of symptoms. Next, the raw score is
calculated by summing the numerical equivalents of the responses
for each item (however, item 12 is not included in the calculation
because there are no numeric equivalents for that item). Then, the
raw score is transformed to a 0 to 100 scale as follows: the total
raw score is divided by the total maximum score multiplied by 100.
A score can still be calculated as follows using the same method
if there are missing responses as long as there are responses to
at least 90% of the items: (sum of the completed items)/(maximum possible sum of the completed items) × 100. For details see
https://www.sportsmed.org/AOSSMIMIS/members/downloads/
research/ScoringInstructions.pdf.
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Score Interpretation. Scores range from 0 to 100, with
higher scores indicating better function and fewer symptoms. A
score of 100 is interpreted to mean no limitation with sporting
activities or daily living and the complete absence of symptoms.
In a cross-sectional survey of 2000 US children and adolescents
aged 10 to 18 years who reported data on their “index knee”
and reported recent (4-week) activity limitations, the mean ± SD
score was 86.7 ± 16.8, and the median was 94.6. Participants
who reported prior surgery or limited activity in the index knee
had median Pedi-IKDC scores that were approximately 25 points
lower than participants without these histories (P < 0.0001 for
both comparisons) (79).
Respondent time to complete. The Pedi-
IKDC takes
approximately 10 minutes to complete.
Administrative burden. It takes approximately 10 minutes to administer the Pedi-IKDC and roughly 5 minutes to score
by hand. No software or special equipment is needed to administer or score the Pedi-IKDC.
Translations/adaptations. The Pedi-IKDC is available in
English, Danish, and Dutch. There is no short form version of the
Pedi-IKDC. Sabatino et al (80) developed an electronic version of
the Pedi-IKDC and found it correlated highly with the paper version
(0.946; P < 0.001). The electronic version does not require manual
scoring and was preferred by patients over the paper form. Mellor
et al (81) examined agreement between the paper format and a
text message delivery format of the Pedi-IKDC; the ICC between
the paper and mobile phone delivery of the Pedi-IKDC was 0.96
(P < 0.001; 95% CI 0.93-0.98) (Table 1).

Psychometric information
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and answer. Modifications to directions, item formatting, and
definitions were recommended for the Pedi-
IKDC to ensure
comprehensibility and validity (78). The Dutch translation of the
Pedi-
IKDC demonstrated adequate content validity (more of
than 75% relevant) and adequate construct validity (75% confirmed hypotheses) (76). Discriminant validity was established
because children who reported prior surgery or limited activity in
the index knee had median Pedi-IKDC scores that were significantly lower, by approximately 25 points, than participants without these histories (79).
Responsiveness. A large effect size (1.36) was found for
children undergoing surgical treatment for their knee condition
with an SRM of 0.9 to 1.35 (82,83). Adequate responsiveness
was found in the Dutch translation (more than 75% confirmed
hypotheses) (76).
Minimally important differences. The MCID 12.0 (SD
1.35) (82). The SDC has been reported as 23.8 (76) and 11.3 (83).
Generalizability. The Pedi-IDKC is not to be used with
children under 10 years of age or children with literacy limitations.
The Pedi-IDKC can be used to detect changes in knee outcomes
following surgical procedures (84–87) and rehabilitation (76).
Use in clinical trials. The Pedi-IKDC has been used in
studies of surgical interventions (84–88) and nonsurgical interventions (76) in children with ligamentous injuries and other musculoskeletal conditions (Table 2).

Critical appraisal of overall value to the
rheumatology community

Floor and ceiling effects. For the Pedi-IKDC total score,
the floor effect was 0% and the ceiling effect was 1%. There were
five individual items that demonstrated a ceiling effect greater than
30% and 16 items that were over 15%. None of the 18 items
demonstrated an unacceptable floor effect of more than 30%;
however, six items had a floor effect greater than 15% (82). In the
Dutch version, low floor or ceiling effects (scores between 5 and
95) were observed (76).

The lack of a sex-based effect and the minor variation in
scores with age within a sample 2000 US children suggest that
the Pedi-IKDC may be easy to interpret and Pedi-IKDC score
distributions can provide assumptions for use in sample size or
power calculations for research. Additionally, in a study comparing
Dutch children with knee disorders, the Pedi-IKDC appeared to
demonstrate slightly better psychometric properties (76). Limitations of the Pedi-IKDC are that the tool can demonstrate large
ceiling effects (82) and that it is lengthy and can potentially fatigue
patients.

Reliability. The Pedi-IKDC has high internal consistency
(Cronbach’s α coefficients ranged from 0.90 to 0.91). The test-
retest reliability is excellent (ICC = 0.9) (82). The SEM has been
reported at 4.1 (83) and 8.6 (76).

Summary/recommendations

Validity. Face validity was assessed with cognitive interviewing. Content validity of the IDKC was examined with 30
children experiencing a primary knee injury. Children found the
IKDC Subjective Knee Evaluation Form difficult to comprehend

The Pedi-IKDC is simple to administer and easy to comprehend and to score. It demonstrates excellent psychometric properties, including an MCID, and has published normative values.
The Pedi-IKDC has been used in numerous studies of orthopedic
interventions. It is not be used in children younger than 10 years
of age.
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PATIENT-R EPORTED OUTCOMES
MEASUREMENT INFORMATION SYSTEM
PEDIATRIC PHYSICAL FUNCTION SCALE
Description
Purpose. The PROMIS-PF is a generic PF PROM that
has been used for patients or clients with musculoskeletal
disorders, including arthritis. The PROMIS-PF, a component
of the overall Patient-Reported Outcomes Measurement System (PROMIS), is a comprehensive measurement set based
on item response theory (IRT) that is designed to evaluate
physical, mental, and social health in both adults and children. The PROMIS-PF pediatric version measures PF (mobility and UE function) through a grading scale of ADLs. Note
that there are different versions of PROMIS available, and
PROMIS measures are copyrighted. There are two versions
of the pediatric PROMIS-PF; version 2 has replaced the original version.
Content or domains. The PF subscale includes mobility
and UE function items.
Number of items. There are 24 items in the item bank for
PF, with the short form having eight items (88). The number of
items can be variable depending on whether the static short form,
off-the-shelf or customized, or the computerized adaptive IRT format is used. The computerized IRT format calibrates each item of
the trait along a measurement continuum and characterizes the
probability of the respondent’s level on the construct based on
the response option chosen for a calibrated item (eg, if a child
indicates he/she can run a block then the child can skip the item
regarding walking).
Response options/scale. A five-point ordinal scale is used
to indicate ability to perform the activity, with values ranging from
5 (without any difficulty) to 1 (unable to do). Note that version 1.0
used a 0 to 4 ordinal scale that was updated to the 1 to 5 scale
in version 2.
Recall period. Respondents are asked to consider their
experiences over the past 7 days.
Cost to use. English and Spanish PROMIS versions are
publicly available for use in research, clinical practice, educational
assessment, or other application without licensing or royalty fees.
Commercial users must seek permission to use, reproduce, or
distribute measures. Integration into proprietary technology also
requires written permission. For details, please see http://www.
healthmeasures.net/images/PROMIS/Terms_of_Use_HM_appro
ved_1-12-17_-_Updated_Copyright_Notices.pdf.
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How to obtain. To access the various versions of the
PROMIS-PF go to http://www.healthmeasures.net/explore-mea
surement-systems/promis/obtain-administer-measures.

Practical application
Method of administration. In the pediatric population,
the PROMIS-PF can be administered to children without help
from anyone else or if they are unable to complete the survey
on their own, a parent/guardian proxy report can be obtained
(89). The PROMIS website provides best practices for the
administration of the survey. PROMIS can be completed with
pen and paper (short form and profiles), via computer adaptive
testing, and via an app. The computer adaptive versions, also
referred to as the computer adaptive test (CAT) short forms
and profiles, can be administered using Research Electronic
Data Capture (REDCap), a secure web system that can build
surveys, manage administration, and calculate scores from the
PROMIS surveys. Please visit https://proje
ctred
cap.org/soft
ware/ for more information about REDCap and the REDCap
Library or contact the REDCap team at redcap@vumc.org.
PROMIS has also been integrated into Epic, an electronic medical record system in version 2012 and onward. With respect
to use of apps, PROMIS is available via the PROMIS iPad app
and the National Institutes of Health Toolbox iPad app. Please
visit http://www.healthmeasures.net/index.php?option=com_
content&view=category&layout=blog&id=132&Itemid=936.
Scoring. It is strongly recommended to use the automated
scoring system, which is freely available after registration (90).
The HealthMeasures scoring service is especially useful when the
short form is administered and participants skip items, different
groups of participants respond to different items, or you create
a new subset of questions from one of the HealthMeasures (eg,
PROMIS) item banks. PROMIS has a published scoring manual
that can be found at http://www.healt
hmeas
ures.net/image
s/
PROMIS/manuals/PROMIS_Physical_Function_Scoring_Manual.
pdf.
Score interpretation. Scores are standardized using a
T score metric in which 50 is the mean of a relevant reference
population and 10 is the SD of that population. Thus, a higher T
score reflects higher (better) PF and a lower T score reflects lower
(worse) PF. Normative values exist for this measure. Morgan et al
(91) established cut points for the PROMIS-PF among children
with JIA for UE function as follows: more than 35 = no problems,
35 to 25 = mild problems, 24 to 20 = moderate problems, and
less than 20 = severe problems. For the mobility scale the values include the following: more than 40 = no problems, 40 to
30 = mild problems, 29 to 25 = moderate problems, and less than
25 = severe problems.
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Respondent time to complete. Time to complete is variable depending on the format used (eg, the short form is estimated to take 15 minutes, and the CAT IRT format depends on
the respondent’s functional level because items can be eliminated
based on the respondent’s answers).
Administrative burden. Time for child or parent proxy to
complete is 15 minutes. There is software to provide a computer-
based version (see above) of the PROMIS-PF pediatric version.
For software needed for scoring see Scoring.
Translations/adaptations. The PROMIS-PF is available
in English, Spanish, French, German, and many other languages.
For a full list of languages see http://www.healthmeasures.net/
explore-measurement-systems/promis/intro-to-promis/availabletranslations. Only the English and Spanish versions are available
to download for free. To request any other language, please contact translations@HealthMeasures.net. (Table 1)

Psychometric information
Floor and ceiling effects. The PROMIS-
PF showed
acceptable floor and ceiling effects (less than 15%) in 100
youth presenting with knee pain (92). In a population of children
from general and specialty pediatric clinics, a ceiling effect was
found (93). The short form version had less variability of scores
than the CAT version did, indicating that the CAT version is
better able to measure function for children at the high ends
of the scale.
Reliability. Varni et al (93) examined the psychometric properties of the PROMIS-PF in 331 children ages 8 to 17 years who
were recruited from general pediatric and subspecialty clinics. The
internal consistency, as measured by Cronbach’s α of the mobility
and UE subscales, ranged from 0.62 to 0.77. The test-retest reliability of the PROMIS-PF was assessed in 54 children at baseline
and 2 weeks later and was found to be good, with a correlation
of 0.70 (93).
Validity. Content validity was confirmed via an extensive
literature search followed by focus groups, cognitive interviews,
and pilot testing among a diverse group of individuals, which were
performed to enhance the relevance of items and clarify language.
In a prospective study of 100 individuals with knee pain, Schafer
et al (92) collected PROMIS scores and Pedi-IKDC scores and
found that Pedi-IKDC scores correlated with the mobility (r = 0.42)
and pain interference (r = −0.49) PROMIS scales. When seven
highly functioning individuals with significant pain were removed
for a secondary analysis, the mobility and pain interference correlations improved to 0.69 and −0.67, respectively.
Waljee et al (94) examined construct validity of the
PROMIS-
PF UE scale in 33 children (ages 6-
17 years) with
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 ongenital hand differences and reported good construct validity.
c
The short form and CAT versions were highly correlated with disabilities of the arm, shoulder, and hand scores (r > 0.80; P < 0.001)
and all PODCI domains except for sports (r > 0.70; P < 0.001).
Correlation with the Michigan Hand Questionnaire was moderate
(r > 0.40; P < 0.05). PROMIS short form and CAT scores also correlated with grip strength (r ≥ 0.60; P < 0.001) and pinch strength
(r ≥ 0.50; P < 0.001).
Responsiveness. The pediatric PROMIS-
PF responsiveness has been assessed in a variety of patient groups (eg, children
with asthma, sickle cell disease, following abdominal surgery, and
chronic pain).
Minimally important differences. Thissen et al (95)
identified a MCID of 2 to 3 points on the mobility scale, whereas
Morgan and colleagues (91) found that estimates of minimally
important differences varied by domain, the severity of symptom/
dysfunction, and by who was making the judgment (pediatric
patient, parent, or clinician).
Generalizability. The pediatric PROMIS-PF is a generic
PF measure for children and their parent proxy and has been used
in healthy and numerous health conditions.
Use in clinical trials. The PROMIS-PF has been shown
useful in measuring the PF (mobility and UE function) of children
with various conditions in numerous studies of the effectiveness
of interventions and quality of clinical care in routine practice
(Table 2).

Critical appraisal of overall value to the
rheumatology community
The PROMIS-PF is a generic PF measure for children and
their parents that has many advantages. First, item banks can
be created for each health attribute to allow for greater precision of measurement at various levels of an attribute, whereas
respondents need only answer a subset of relevant items related
to their ability to perform a specific trait. Secondly, a CAT format
is more time efficient and less burdensome. PROMIS has an
electronic scoring system that converts scores to standardized
values, minimizing administrative burden. The psychometric properties are well established and strong, and normative values exist
for comparison. There is an established MCID for the pediatric PF
score, and the PROMIS-PF is available in numerous languages.

Summary/recommendations
The pediatric PROMIS-PF is a generic measure of mobility
and UE function in children. It has strong psychometric properties, is easy to comprehend, and can be administered in various
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formats. The PROMIS-PF for children has been extensively used
in clinical trials and in clinical practice across the globe and has
established normative values. Thus, the PROMIS-PF allows for
comparison of treatment effectiveness across a variety of conditions. Although the scoring is complex, a training manual and an
Excel file with embedded formulas are available to assist researchers and clinicians.

Practical application

ACTIVITY SCALE FOR KIDS

Scoring. Each version (the ASKp and the ASKc) includes
instructions in the test booklet and an instruction card the child
can use while completing each item. The five-point (0-4) ordinal
scale is scored as follows: 4 points for 0, 3 points for 1, 2 points
for 2, 1 point for 3, and 0 points for 4. The summary score does
not include the N/A option. Scores on the 30 individual activity
items (or the number completed by the child minus any N/A items)
are tabulated by averaging the responses and then multiplying by
25 in order to convert the score to a 0 to 100 range.

Description
Purpose. The ASK was developed to assess various ADLs
and physical activity–related function in children ages 5 to 15
years with musculoskeletal disorders (96). The ASK includes two
versions, one that measures a child’s physical capability in his/her
daily environment (the ASK capability [ASKc]) and one that measures the child’s performance of the same activities in their daily
environment (the ASK performance [ASKp]).
Content/domains. The ASKc measures activities the child
could have done (capability), and the ASKp measures activities
the child actually did do over the past week. The ASK includes
seven domains, including personal care, dressing, other skills,
locomotion, play, standing skills, and transfers.
Number of items. There are 30 items in the original version
of the ASK. The revised version contains 38 items (97).
Response options/scale. Both versions include a five-
point ordinal scale response option (range: 0-4). The response
options depend on the ASK version. For the ASKc, 0 = with no
problem, 1 = with a little problem, 2 = with a moderate problem,
3 = with a big problem, and 4 = I could not. For the ASKp, 0 = all
of the time, 1 = most of the time, 2 = sometimes, 3 = once in a
while, and 4 = none of the time.
Recall period. The recall period is over the past week.
Cost to use. The cost to use ASK is variable and depends upon
purpose for use (clinician versus funded researcher). Prices can be
found at the ASK website (http://www.activitiesscaleforkids.com/).
How to obtain. Those interested in obtaining the ASK must
visit the ASK website (http://www.activitiesscaleforkids.com/) and
register to use the tool. It is free to academics and students for
student projects or teaching purposes. Researchers and clinicians must provide payment. The cost for clinicians is less than
for researchers, and researcher fees vary depending on whether
a researcher is funded or not (costs range from 150 Canadian
dollars [CAD]/year to 900 CAD/year).

Method of administration. Children are given a booklet
to complete using a pen or pencil. Children under 9 years of age
and those with cognitive impairments may require assistance with
reading the items; however, the child is expected to record the
response. The ASK should be completed in a child’s home environment. The ASK can also be administered via postal mail.

Score interpretation. A lower score indicates greater disability. The ASK was given to 122 healthy children; the average
score was 93.12 (SD 6.45) (98). This score was significantly higher
than the mean summary score for children with mild disability in
previous studies (P = 0.005) (98).
Respondent time to complete. The ASK takes approximately 30 minutes to complete for the first time but takes as little
as 10 minutes on subsequent administrations (97).
Administrative burden. Administrative burden is low
because the ASK is not lengthy and does not require any special equipment or training. Administrators should read the instruction manual prior to the administration of the ASK.
Translations/adaptations. Feldman et al (96) created a
revised version of the ASK, which was rescaled from the original.
The ASK website indicates that the ASK is available in Canadian
English, Canadian French, UK English, Spanish, and Dutch (Table 1).

Psychometric information
Floor and ceiling effects. The ASK shows no floor effects
and minimal ceiling effects (99).
Reliability. In a study of 74 children with JIA of mixed subtypes, the test-retest reliability of the revised ASK demonstrated
excellent reliability (ICC = 0.91) (31). In a study by Young et al (100)
in which the ASK was mailed to 40 parents and children twice,
the test-retest reliability was also good (ICC = 0.97 for ASKp and
ICC = 0.98 for ASKc.) Internal consistency reliability was excellent,
with a Cronbach’s α of 0.99.
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Validity. With regard to criterion validity, Young et al (100)
found that when tested with a group of 200 children, the ASK was
strongly correlated with parent-reported C-HAQ scores (r = 0.81)
and clinician observation (r = 0.92). In addition, they found a significant difference in ASK scores according to the clinician’s global
ratings of disability (P < 0.001). Young et al (100) also demonstrated construct validity with Rasch analyses, which confirmed
that all items measure the same construct.

clinicians and researchers an added dimension of PF. Although
the ASK is easy to administer and score, the fees are quite high
for researchers and clinicians compared with other measures with

Responsiveness. The responsiveness of the ASK was
assessed with 34 children who completed the ASK and C-HAQ
before and after a clinically important change. Twenty-three of the
children improved and 11 children worsened. The resultant effect
sizes indicate that the ASK performance is responsive. Specifically, the ASKp was 16% more responsive than the C-HAQ, and
the ASKc was 2% less responsive than the C-HAQ (31).
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JAMAR

PODCI

JASI

JAFAS

The C-HAQ-30 has Self-report for
children 9 y old
eight domains
or older;
(dressing and
guardian/proxy
grooming,
for children <9 y
arising, eating,
old
walking, hygiene,
reach, grip, and
activities); the
C-HAQ-38 has no
domains.
Observation by
10 ADLs
ADLs (getting out
OT or PT of
of bed, dressing,
current function
and picking an
object up off the
floor)
100 items for Part JASI Part I has five Child completes
Part I on
domains
I; 5 items for
computer
(self-care,
Part II
(20-45 min);
domestic,
child is
mobility, school,
interviewed for
and
Part II (~20
extracurricular)
minutes).
Subscales include Guardian proxy
Original version
for children
upper extremity
had 114 items;
(2-10 y);
and physical
newer version
self-report for
function,
has 83 items for
adolescents
transfers and
the adolescent
(11-18 y)
basic mobility,
version and 86
sports and
items for the
physical
parent version.
function, pain/
comfort,
happiness and a
global function
score.
33 items
Total PF score has Can be used as
both a proxy
three
report and a
components: PF
patient
lower limbs, PF
self-report (age
hand and wrist,
7-18 y for
and PF upper
self-report)
segment; the
HRQoL includes
two
subdimensions:
physical health
and psychosocial
health.

30 items for the
C-HAQ-30; 38
items for the
C-HAQ-38

C-HAQ

Method of
Administration

Number of Items Content/Domains

Practical applications*

Measure

Table 1.

Differs
according to
the specific
measure

Some Likert
scales,
nominal
items, and
VAS scales.

PF score
(0-45).
HRQoL
score (0-30)

Some nominal 0-100
items (yes/
no) and
some Likert
scales (either
a four-point
or five-point
scale)

Past week for
all items
except for
one item
that asks for
recall of 1 y

Cross-cultural
Validation

|

(Continued)

Available in >50
countries (see
content
description)

None available

Higher score =
greater disability

None

Normative score of Available in
Korean, Dutch,
mean = 50 (SD =
Spanish, Polish,
10)
Turkish, and
Brazilian
Portuguese

Criterion-
referenced test

Available in >30
The median
countries (see
C-HAQ-30 scores
Content)
corresponding
with mild, mild to
moderate, and
moderate
disability were
0.13, 0.63, and
1.75, respectively
(21).
None
India

Availability of
Normative Data

Higher score = less
disability

Lower score =
greater disability

Part I: 0-600;
Part II: 0-30

Seven-point
degree of
difficulty
rating scale

Current status

Higher score =
greater disability

0-20

Three-point
scale based
on task
completion.

N/A

Higher score =
greater disability

Score
Interpretation

0-3

Range of
Scores

Four-point
Likert scale

Response
Format

Past week

Recall Period
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13 items

30 items in the
original version;
38 items in the
revised version

Pedi-IKDC

ASK

Past week
Completed by
Seven domains:
child (ages
personal care,
9-15 y); parent
dressing, other
may read items
skills,
to child younger
locomotion, play,
than 9 y
standing skills,
and transfers

Score
Interpretation

0-100

Higher score = less
disability

Higher score =
better function

0-100 for each A score of 100 = no
subscale
symptoms; a
score of 0 =
extreme
symptoms

Range of
Scores

0-100
Children
compare
their ability
to perform
the activities
with that of
their healthy
peers (−2 =
much worse,
0 = the same
as, and 2 =
much better)

Some Likert
Most items
scales,
over the past
categorical
4 wk; some
items, VAS
items based
scales, and
on whether
nominal
they could
items
do the
activity today

Paper-and-pencil
Physical function,
administration
participation in
sports/
recreation, ADLs,
demographic,
and medical
history items

Five-point
Likert scales

Response
Format

Past week

Recall Period

Completed using
Five subscales:
paper and pen
knee pain, knee
and can be
symptoms, ADLs,
administered in
sports and play,
person or via
and quality of life
postal mail

Method of
Administration

Cross-cultural
Validation

Normative data are Available in
Danish, Dutch,
reported for
English,
children 8-17 y
Finnish, Greek,
old (see Content)
Norwegian,
Persian, and
Swedish
Available in
In data on index
English, Danish,
knee among
and Dutch
children who
reported recent
(4-wk) activity
limitations the
mean ± SD score
was 86.7 ± 16.8,
and the median
was 94.6.
Available in
Average score
Canadian
among healthy
English,
children was
Canadian
93.12 (SD = 6.45).
French, UK
English,
Spanish, and
Dutch

Availability of
Normative Data

* ADL = activity of daily living; ASK = Activity Scale for Kids; C-HAQ = Child Health Assessment Questionnaire; HRQoL = Pediatric Rheumatology Quality of Life Scale; JAFAS = Juvenile Arthritis
Functional Assessment Scale; JAMAR = Juvenile Arthritis Multidimensional Assessment Report; JASI = Juvenile Arthritis Self-Report Index; KOOS-Child = Knee Osteoarthritis Outcome Survey
for Children; N/A = not applicable; OT = occupational therapist; Pedi-IKDC = International Knee Documentation Committee Subjective Knee Evaluation Form in Children; PF = physical
function; PODCI = Pediatric Outcomes Data Collection Instrument; PT = physical therapist; VAS = visual analog scale.

39 items

Number of Items Content/Domains

(Cont’d)

KOOS-
Child

Measure

Table 1.
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None reported

ASK

Not to be used in
children under 10
years old or those
with literacy
limitations
Generic physical
function measure for
children and their
parent proxy that has
been used in healthy
children and those
with numerous health
conditions
Used for children (ages
5-15 years) with
musculoskeletal
conditions, including
arthritis

MCID = 12 (SD =
1.35)

MCID = 2-3 points

Excellent internal consistency
(Cronbach’s α = 0.99), excellent
test-retest reliability (ICC =
0.91-0.97), and excellent
interrater reliability (r = 0.99)

Moderate internal consistency
(Cronbach’s α = 0.62-0.77);
moderate test-retest (r = 0.7)

Good to excellent content
validity, excellent
construct validity, and
good to excellent
convergent validity with
measures of disease
activity (r = 0.81-0.92)

Good to excellent (SRM
= 1.1 for parent and
SRM = 0.94 for child)

Excellent face and content
validity (>75% relevant),
adequate construct
validity (75% hypotheses
confirmed), and
excellent discriminant
validity
Established in a variety
Excellent content validity,
of conditions (eg,
moderate to good
asthma and after
construct validity (r =
abdominal surgery)
0.4-0.8), and moderate
to good convergent
validity (r = 0.42-0.69

Not established

For use in children 10 to
16 years old with
musculoskeletal
conditions or injuries

MCID = 24.7-46.9

Excellent internal consistency
(Cronbach’s α = 0.8-0.9 except
symptoms, α = 0.59); good to
excellent test-retest reliability
(ICC = 0.78-91)
Excellent internal consistency
(Cronbach’s α = 0.90-0.91);
excellent test-retest reliability
(ICC = 0.9)

Moderate ES (0.42-0.78)
for those with
improvement and low
ES for those with
stable symptoms
Excellent (ES= 1.36; SRM
= 0.9-1.35)

Good

Excellent content validity;
good construct validity
(all hypotheses
confirmed)

Used for children with a
variety of
musculoskeletal
conditions

Yes in children with
CP

Moderate SEM = 0.36

Good content validity;
construct validity
moderate to good (r =
0.51-0.80)
Excellent content,
convergent good,
discriminant good

Test-retest reliability is good to
excellent for Part I (ICC =
0.98-0.99) and for Part II, (κ =
0.57)
Good to excellent internal
consistency (Cronbach’s α =
0.82-0.95) Test-retest good to
excellent (0.71-0.97)

Used in a variety of
arthritis conditions
(JIA, juvenile DM,
active juvenile SLE,
juvenile IIM, CP, and
generalized
musculoskeletal pain)
Not appropriate for
children aged 7 years
and younger

For children with
JIA, the MCID for
improvement =
0.188 at most
and the MCID for
worsening =
+0.125.
Not at this time

Strong responsiveness
for all three versions
of the C-HAQ, with
VASC-HAQ having
themost
responsiveness

Excellent content validity;
moderate to good
convergent validity with
disease activity
measures

Generalizability

Excellent reliability (Cronbach’s α
= 0.9); test-retest rs = 0.8;
interrater strong (0.54-0.84)

Responsiveness

Validity

Reliability

Minimally
Important
Differences

Yes

Yes

Yes

Yes

Yes

Limited

Yes

Used in
RCTs

* ASK = Activity Scale for Kids; C-HAQ = Child Health Assessment Questionnaire; CP = cerebral palsy; ES = effect size; ICC = interclass correlation coefficient; IIM = idiopathic inflammatory
myopathy; JAMAR = Juvenile Arthritis Multidimensional Assessment Report; JASI = Juvenile Arthritis Self-Report Index; JIA = juvenile idiopathic arthritis; KOOS-Child = Knee Osteoarthritis
Outcome Survey for Children; MCID = minimal clinical important difference, Pedi-IKDC = International Knee Documentation Committee Subjective Knee Evaluation Form in Children; PODCI =
Pediatric Outcomes Data Collection Instrument; PROMIS-PF = Patient-Reported Outcomes Measurement Information System–Physical Function Scale; RCT = randomized controlled trial;
SLE = systemic lupus erythematosus; SRM = standardized response mean; VAS = visual analog scale.

None (<15%)

Low (<15%)

JAMAR
KOOS-Child

PROMIS-PF

None reported

PODCI

Low; six items had
a floor effect of
>15% but did not
hit critical
threshold of 30%

None reported

JASI

Pedi-IKDC

Yes, for original
C-HAQ; no, for
revised version,
C-HAQ38

C-HAQ

Floor and Ceiling
Effects

Psychometrics*

Measure

Table 2.
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